Literature DB >> 18808401

COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of 'switching on' hallucinations in the flow of daily life.

C Henquet1, A Rosa, P Delespaul, S Papiol, L Fananás, J van Os, I Myin-Germeys.   

Abstract

OBJECTIVE: A functional polymorphism in the catechol-o-methyltransferase gene (COMT Val(158)Met) may moderate the psychosis-inducing effects of cannabis. In order to extend this finding to dynamic effects in the flow of daily life, a momentary assessment study of psychotic symptoms in response to cannabis use was conducted.
METHOD: The experience sampling technique was used to collect data on cannabis use and occurrence of symptoms in daily life in patients with a psychotic disorder (n = 31) and healthy controls (n = 25).
RESULTS: Carriers of the COMT Val(158)Met Val allele, but not subjects with the Met/Met genotype, showed an increase in hallucinations after cannabis exposure, conditional on prior evidence of psychometric psychosis liability.
CONCLUSION: The findings confirm that in people with psychometric evidence of psychosis liability, COMT Val(158)Met genotype moderates the association between cannabis and psychotic phenomena in the flow of daily life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18808401     DOI: 10.1111/j.1600-0447.2008.01265.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  25 in total

Review 1.  Genetically informative research on adolescent substance use: methods, findings, and challenges.

Authors:  Michael T Lynskey; Arpana Agrawal; Andrew C Heath
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-10-20       Impact factor: 8.829

Review 2.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 3.  Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome.

Authors:  Didier Jutras-Aswad; Jennifer A DiNieri; Tibor Harkany; Yasmin L Hurd
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

Review 4.  Cannabis controversies: how genetics can inform the study of comorbidity.

Authors:  Arpana Agrawal; Michael T Lynskey
Journal:  Addiction       Date:  2014-01-19       Impact factor: 6.526

Review 5.  The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research.

Authors:  Conrad Iyegbe; Desmond Campbell; Amy Butler; Olesya Ajnakina; Pak Sham
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-01-17       Impact factor: 4.328

Review 6.  Genes, cognition and brain through a COMT lens.

Authors:  D Dickinson; B Elvevåg
Journal:  Neuroscience       Date:  2009-05-13       Impact factor: 3.590

Review 7.  Ambulatory assessment.

Authors:  Timothy J Trull; Ulrich Ebner-Priemer
Journal:  Annu Rev Clin Psychol       Date:  2012-11-13       Impact factor: 18.561

Review 8.  Epigenetic mediation of environmental influences in major psychotic disorders.

Authors:  Bart P F Rutten; Jonathan Mill
Journal:  Schizophr Bull       Date:  2009-09-25       Impact factor: 9.306

Review 9.  Cannabis and development of dual diagnoses: A literature review.

Authors:  Rebecca C Hanna; Jessica M Perez; Subroto Ghose
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-09       Impact factor: 3.829

10.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.